![Henrik Stage](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Henrik Stage
Keine laufenden Positionen mehr
Profil
Henrik Stage is the founder of Skape Bio ApS, founded in 2025, holding the title of Director.
Mr. Stage was the founder of ADCendo ApS, founded in 2017, holding the title of Chief Financial Officer from 2021 to 2022.
Stage is also the founder of Fuse Vectors ApS..
Mr. Stage is currently Chairman at Biomia ApS since 2022.
Stage is currently Director at ResoTher Pharma AS.
Stage is currently Director at iNotify ApS.
Stage is currently Partner at Ventac Partners A. Mr. Stage is currently Owner at Next Stage Ventures ApS.
Formerly, Mr. Stage was Chief Executive Officer at RICC A from 2012 to 2014.
Stage was Chief Financial Officer at SynAct Pharma AB from 2016 to 2022.
Stage was Chief Financial Officer at RhoVac AB. Stage completed graduate education at Copenhagen Business School.
Aktive Positionen von Henrik Stage
| Unternehmen | Position | Beginn |
|---|---|---|
Ventac Partners A/S
 Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Provides life science consulting services | Corporate Officer/Principal | - |
ResoTher Pharma AS
 ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Direktor/Vorstandsmitglied | - |
Next Stage Ventures ApS
 Next Stage Ventures ApS Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Henrik Stage
| Unternehmen | Position | Ende |
|---|---|---|
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Vorstandsvorsitzender | 07.07.2021 |
| SYNACT PHARMA AB | Finanzdirektor/CFO | 07.01.2022 |
| CHOSA ONCOLOGY AB | Finanzdirektor/CFO | - |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Vorstandsvorsitzender | 09.01.2014 |
Ausbildung von Henrik Stage
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
5
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Copenhagen Business School
 Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Health Technology |
SynAct Pharma AB
 SynAct Pharma AB Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs for treatment inflammatory diseases | Health Technology |
Ventac Partners A/S
Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Provides life science consulting services | Commercial Services |
RhoVac AB
 RhoVac AB BiotechnologyHealth Technology Engages in the research and development of immunotherapy for therapeutic cancer vaccines | Health Technology |
Next Stage Ventures ApS
Next Stage Ventures ApS Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products | Commercial Services |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops peptide-based drugs | Health Technology |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology Operates as a clinical-stage biotech company that dedicated to developing transformative first and best-in-class antibody-drug conjugate therapies for cancers | Health Technology |
